Last reviewed · How we verify
Mirikizumab - IV
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut. Used for Ulcerative colitis, Crohn's disease.
At a glance
| Generic name | Mirikizumab - IV |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 p19 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
IL-23 is a key cytokine driving Th17 cell differentiation and intestinal inflammation. By blocking the p19 subunit of IL-23, mirikizumab prevents IL-23-mediated immune activation while preserving IL-12 signaling, which is important for antimicrobial immunity. This selective IL-23 inhibition reduces pathogenic T cell responses in inflammatory bowel disease.
Approved indications
- Ulcerative colitis
- Crohn's disease
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reactions
Key clinical trials
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (PHASE3)
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) (PHASE3)
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (PHASE3)
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (PHASE3)
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (PHASE2)
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease (PHASE2)
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (PHASE3)
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: